GlassScriptPhysician profile
Peter G Wernicki
NPI 1902837867
$408.33
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $134 · 2021: $96.47 · 2022: $37.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $98.57 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $75.05 | 2019-2021 | |
| Radius Health, INC. | $58.77 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.01 | 2021 | |
| Smith+Nephew, INC. | $39.55 | 2020 | |
| Scilex Pharmaceuticals INC. | $29.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.91 | 2022 | |
| Bioventus LLC | $17.38 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.42 | 2019 | |
| Horizon Therapeutics Plc | $13.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wernicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.